Ablation of atrial fibrillation with the Epicor system: a prospective observational trial to evaluate safety and efficacy and predictors of success
© Schopka et al; licensee BioMed Central Ltd. 2010
Received: 4 January 2010
Accepted: 5 May 2010
Published: 5 May 2010
High intensity focused ultrasound (HIFU) energy has evolved as a new surgical tool to treat atrial fibrillation (AF). We evaluated safety and efficacy of AF ablation with HIFU and analyzed predictors of success in a prospective clinical study.
From January 2007 to June 2008, 110 patients with AF and concomitant open heart surgery were enrolled into the study. Main underlying heart diseases were aortic valve disease (50%), ischemic heart disease (48%), and mitral valve disease (18%). AF was paroxysmal in 29%, persistent in 31%, and long standing persistent in 40% of patients, lasting for 1 to 240 months (mean 24 months). Mean left atrial diameter was 50 ± 7 mm. Each patient underwent left atrial ablation with the Epicor system prior to open heart surgery. After surgery, the patients were treated with amiodarone and coumadin for 6 months. Follow-up studies including resting ECG, 24 h Holter ECG, and echocardiography were obtained at 6 and 12 months.
All patients had successful application of the system on the beating heart prior to initiation of extracorporeal circulation. On average, 11 ± 1 ultrasound transducer elements were used to create the box lesion. The hand-held probe for additional linear lesions was employed in 83 cases. No device-related deaths occurred. Postoperative pacemaker insertion was necessary in 4 patients. At 6 months, 62% of patients presented with sinus rhythm. No significant changes were noted at 12 months. Type of AF and a left atrial diameter > 50 mm were predictors for failure of AF ablation.
AF ablation with the Epicor system as a concomitant procedure during open heart surgery is safe and acceptably effective. Our overall conversion rate was lower than in previously published reports, which may be related to the lower proportion of isolated mitral valve disease in our study population. Left atrial size may be useful to determine patients who are most likely to benefit from the procedure.
Atrial fibrillation (AF) is the most commonly sustained cardiac rhythm disorder. An estimated 4.5 million people in the European Union and 2.2 million people in North America suffer from paroxysmal or persistent AF . All types of AF are associated with a varying increased risk of stroke and heart failure, and the overall mortality rate is doubled as compared to people with normal sinus rhythm .
In cardiac surgery, the percentage of patients with concomitant AF is increasing because AF is linked to structural heart disease and the number of patients with markedly advanced heart disease is growing. AF has also been identified as an important risk factor for both mortality and morbidity in cardiac surgery . Recent studies have shown that 10-year survival of patients undergoing coronary bypass surgery without conversion of atrial fibrillation into sinus rhythm is reduced by 24% .
The purpose of this study was to evaluate the efficacy of left atrial HIFU ablation of AF with the Epicor Cardiac Ablation System (St. Jude Medical, Maple Grove, MN) as concomitant procedure during open heart surgery and to assess predictors of success.
Materials and methods
Preoperative data of patients enrolled into the study.
Age in years
AF duration in months
30 - 68
27 - 70
Procedures concomitantly conducted to left atrial epicardial ablation, absolute numbers and percentage of total
Percentage of Total
Isolated aortic valve repair/replacement
Aortic valve + CABG
Isolated mitral valve repair/replacement
Mitral valve + CABG
Double valve surgery
Tricuspid valve reconstruction
Ascending aorta replacement
Combined cardiac surgery
Diagnosis and classification of AF were established by standard ECG and holter ECG in all patients prior to admission. AF was defined paroxysmal in 29%, persistent in 31% and long standing persistent in 40% of patients. According to the Cox classification, AF was continuous in 71% and intermittent in 29% of patients. Atrial diameters were significantly smaller in patients with intermittent AF than in patients with continuous AF. 16 patients underwent an ineffective attempt of rhythm control prior to admission.
In all patients, ablation of AF was performed via a midline sternotomy prior to the initiation of extracorporeal circulation for the subsequent cardiosurgical procedure.
The Epicor Positioning and Sizing (PAS) System, which was designed to indicate the proper UltraCinch device size and act as a guide for simple placement of the device was passed behind the superior vena cava through the transverse sinus and the oblique sinus underneath the inferior vena cava. After measurement of the proper size, the sizer was replaced by the UltraCinch ablation device to create a "box" lesion above the ostia of all four pulmonary veins. The two ends of the UltraCinch were approximated with tourniquets to snug the device securely around the left atrium. After flushing of the transducer elements with saline solution the ablation cycles were initiated and automatically progressed by the Epicor Ablation Control System until completion. During the ablation process, that takes about 10 minutes, the surgical preparations for extracorporeal circulation were continued. According to the surgeon's preference additional linear lesions were created with the UltraWand, particularly, a mitral line that extends from the "box" lesion to the mitral valve annulus.
After surgery, all patients were treated with intravenous heparin and amiodarone. With reconvalescence of the patient, anticoagulation (warfarin or coumadin) and antiarrhythmic therapy (amiodarone 200 mg/d) were switched to oral medication and maintained for 6 months. After 6 months continuance of oral anticoagulation was determined on basis of the CHADS2 score. In case of contraindications for amiodarone treatment, the latter was replaced by a beta blocker, preferably sotalol. If AF persisted or recurred external cardioversion/defibrillation was not recommended in the early postoperative period to allow full maturation of the ablation line, which takes up to three month in lesions created by ultrasound. After 6 months Amiodarone was discontinued and replaced by β-blockage.
A physical examination, standard 12-lead ECG, 24-hour Holter monitoring, and transthoracic echocardiography were conducted systematically at 6 and 12 month follow-up visits.
Data were entered into a computerized database and analyzed with a statistical package (STATISTICA; StatSoft, Inc). The descriptive summary of data included mean ± standard deviation and 95% confidence intervals for continuous variables and proportions for categorical variables. Between-group differences were assessed with t-tests and analysis of variance in more than two groups for continuous variables and Fishers exact tests for nominal variables. The significance of variables on the odds of procedure failure was assessed by univariate logistic regression analyses. All reported p-values are two-sided.
All patients had successful application of the system on the beating heart prior to initiation of extracorporeal circulation. On average, 11 ± 1 ultrasound transducer elements were used to create the box lesion. The hand-held probe for additional linear lesions was employed in 83 cases. No device-related or procedure-related complications occurred, particularly no injury of the esophagus, coronary arteries or, phrenic nerve. Within the 30-day period, non-lethal postoperative complications including temporary neurological dysfunction (cognitive disorder) in 6 patients and mild pneumonia in 7 patients were observed. Insertion of a long standing persistent pacemaker was necessary in 4 patients who underwent aortic valve replacement, combined with coronary bypass surgery in 3 patients, and isolated in 1 patient. One patient experienced an episode of atrial flutter 3 months after surgery. and underwent successful interventional ablation with subsequent stable sinus rhythm.
In-hospital, mortality was 3.6%. Two patients each died of mediastinitis and of mesenterial ischemia and retroperitoneal bleeding, respectively. Three out of the 4 patients were > 70 years. The EuroSCORE of these patients was 19.9 on average.
Evaluation of efficacy
All patients were alive at follow-up, complete data on cardiac rhythm were obtained in 98% of cases. Mean follow-up interval was 7.8 months, with 75 patients followed for 6 months and 49 patients for 12 months.
Overall freedom from AF, i.e. stable sinus rhythm, was noted in 62% of patients at 6 months and 65% of patients at 12 months after surgery, which was not significantly different. Postoperative pacemaker stimulation for bradycardia remained necessary in 4 patients.
AF as a common co-morbidity in cardiac surgical patients with a prevalence of AF in about 10% of patients with ischemic heart or aortic disease, and in almost 50% of patients with mitral valve disease [9, 10]. As uncorrected AF is associated with increased morbidity and mortality in patients undergoing cardiac surgery, AF ablation concomitant to cardiac surgery appears to be an efficient measure to improve outcome.
The intention of this prospective study was to assess safety of the Epicor ablation procedure and to identify predictors for success and failure, respectively. Our study population was not biased towards a positive selection. In fact, every consecutive patient who wanted to participate was included, which is also expressed by the average age of 71 years and the EuroSCORE of 7.6. In contrast to previous reports, most of our patients suffered from ischemic heart disease and aortic valve stenosis, while only a minority had mitral valve disease. Twenty-five percent of patients underwent combined cardiac surgery. These patients often have rather complex medical histories and significant co-morbidity. If the cardiac surgery is extended by ablation of AF, the latter procedure should add only minimal risk to the patient. Ultrasound ablation is a particularly appropriate intervention for these patients since no bypass or cross clamp time is added to the procedure. In contrast to an endocardial ablation, atriotomy is not required as ultrasound is applied epicardially on the beating heart. Accordingly, an Epicor ablation may also be performed in off-pump CABG and as a stand-alone procedure. A previous report from Ninet et al. already stated an excellent safety of the system, which is consistent with our experience. We did not observe any procedure-related adverse event or postoperative complication, and the need for a postoperative pacemaker implantation was low .
An appropriate postoperative management is important after AF surgery. Since the maturation of the transmural lesions and the electrical isolation of arrhythmic foci may take up to 3 months, electrical cardioversion was avoided during this period. Instead, patients were treated with amiodarone to reduce the occurrence of arrhythmia during the early phase after surgery [11, 12]. As an evaluation of success is not possible within the first 3 months, the first follow-up visit was scheduled at 6 months after surgery.
The overall freedom from AF with 65% was lower than in previous publications with success rates of about 85% [13, 6]. This difference cannot be proven by less efficiency of the ablation system since no interventional electrophysiological studies could be performed during the follow-up visits. However, one may speculate whether the underlying heart diseases did also influence outcome. Our patient cohort mainly suffered from ischemic heart disease and aortic valve stenosis in contrast to previous studies, where mitral valve disease was predominant [6, 13]. It is well known, that mere mitral valve surgery (without additional AF ablation) had a significant beneficial effect on conversion to sinus rhythm [14, 15]. Accordingly, in prior publications, success rates after ablation of AF were typically superior in patients undergoing mitral valve surgery . A recent study on patients with ischemic heart disease has shown 77% freedom from AF, which is comparable to our results .
As has also been shown by others, patients with paroxysmal AF showed a high success rate, significantly better than those with persistent or long standing persistent AF [6, 13]. These patients usually suffer from less pathologic alterations of the myocardium including myocyte size, wall thickness, fibrotic changes and left atrial size.
Nevertheless, is should not be forgotten that these good results may have been a result of inadequate diagnostic measures to detect short periods of AF during follow-up exams. Therefore, we now favor the implantation of event recorders in patients who undergo AF ablation.
Our logistic regression analysis presented preoperative LA size as the strongest predictor of the procedure's failure or success, respectively. At a cut-off point of 50 mm failure rate dramatically worsened with an odd ratio of 4.2. The consequences of left atrial enlargement is less well understood, but it has been assumed that the arrhythmogenic foci known to trigger AF are then more likely to reside in the left atrium than in pulmonary veins [17, 18]. In the literature, the duration of AF also showed to have a predictive value but this could not be confirmed in our analysis [6, 7]. However, the duration of AF was usually obtained via the medical history, which is of limited reliability because of the common occurrence of asymptomatic AF.
The size of the transducer system, i.e. the number of transducer elements, was not predictive too, and did not correlate with echocardiographically measured left atrial size.
In conclusion, we found the ultrasound epicardial ablation of AF with the Epicor system, concomitantly applied with cardiac surgery, to be a safe procedure. Effectiveness of the ablation depends on the primary diagnosis as well as on the preoperative left atrial size. Thus, these variables may serve as a tool to preoperatively identify patients who are most likely to benefit from this procedure. Further analysis of the Epicor registry, a multicenter registry of patients undergoing ultrasound ablation, is going to overcome the major limitation of the present study, i.e. the low number of study participants.
Limitations of the study
The results of this study are limitated by the inhomogenous study population, which is partly founded in the fact that patients have been recruited consecutively. Another limitation is the duration of follow up. The manuscript presents data of the first 110 patients treated with this device in the center, analysis of a multicenter registry will follow. The most important limitation is the inhomogenous usage of the additional device creating a mitral line, further analysis will focus on regular usage of this device and study its influence on freedom of AF.
- Feinberg WM, Cornell ES, Nightingale SD, Pearce LA, Tracy RP, Hart RG, Bovill EG: Relationship between prothrombin actvation fragment F 1.2 and international normalized ratio in patients with atrial fibrillation. Stroke prevention in atrial fibrillation investigators. Stroke. 1997, 28: 1101-6.View ArticlePubMedGoogle Scholar
- Krahn AD, Manfreda J, Tate RB, Mathewson FA, Cuddy TE: The natural history of atrial fibrillation: incidence, risk factors and prognosis in the Manitoba follow up study. Am J Med. 1995, 98: 476-84. 10.1016/S0002-9343(99)80348-9.View ArticlePubMedGoogle Scholar
- Sergeant P, Blackstone EH, Meyns B: Validation and interdependence with patient-variables of the influence of procedural variables on early and late survival after CABG. Eur J Cardiothoracic Surg. 1997, 12: 1-19. 10.1016/S1010-7940(97)00134-6.View ArticleGoogle Scholar
- Quader MA, McCarthy PM, Gillinov AM, Alster JM, Cosgrove DM, Lytle BW, Blackstone EH: Does preoperative atrial fibrillation reduce survival after coronary artery bypass grafting?. Ann Thorac Surg. 2004, 77: 1514-11522. 10.1016/j.athoracsur.2003.09.069.View ArticlePubMedGoogle Scholar
- Prasad SM, Maniar HS, Camillo CJ, Schuessler RB, Boineau JP, Sundt TM, Cox JL, Damiano RJ: The Cox maze III procedure for atrial fibrillation: long-term efficacy in patients undergoing lone versus cocncomitant procedures. J Thorac Cardiovasc Surg. 2003, 126: 1822-8. 10.1016/S0022-5223(03)01287-X.View ArticlePubMedGoogle Scholar
- Ninet J, Roques X, Seitelberger R, Deville C, Pomar JL, Robin J, Jegaden O, Wellens F, Wolner E, Vedrinne C, Gottardi R, Orrit J, Billes MA, Hoffmann DA, Cox JL, Champsaur GL: Surgical ablation of atrial fibrillation with off-pump, epicardial, high-intensity focused ultrasound: Results of a multicenter trial. J Thorac Cardiovasc Surg. 130: 803-9.
- Gillinov AM, Petterson G, Rice TW: Esophageal injury during radiofrequency ablation for atrial fibrillation. J Thorac Cardiovasc Surg. 2001, 122: 1239-40. 10.1067/mtc.2001.118041.View ArticlePubMedGoogle Scholar
- Manasse E, Medici D, Ghiselli S, Ornaghi D, Gallotti R: Left main coronary arterial lesion after microwave epicardial ablation. Ann Thorac Surg. 2003, 76: 276-7. 10.1016/S0003-4975(03)00141-3.View ArticlePubMedGoogle Scholar
- Eguchi K, Ohtaki E, Matsumura T, Tanaka K, Tohbaru T, Iguchi N, Misu K, Asano R, Nagayama M, Sumiyoshi T, Kasegawa H, Hosoda S: Preoperative atrial fibrillation as the key determinant of outcome of mitral valve repair for degenerative mitral regurgitation. Eur Heart J. 2005, 26: 1866-72. 10.1093/eurheartj/ehi272.View ArticlePubMedGoogle Scholar
- Ngaage DL, Schaff HV, Barnes SA, Sundt TM, Mullany CJ, Dearani JA, Daly RC, Orszulak TA: Prognostic implication of preoperative atrial fibrillation in patients undergoing aortic valve replacement; is there an argument for concomitant arrhythmia surgery?. Ann Thorac Surg. 2006, 82: 1392-9. 10.1016/j.athoracsur.2006.04.004.View ArticlePubMedGoogle Scholar
- Benussi S, Nascimbene S, Agricola E, Calori G, Calvi S, Caldarola A, Oppizzi M, Casati V, Pappone C, Alfieri O: Surgical Ablation of atrial fibrillation using the epicardial radiofrequency approach: mid term results and risk analysis. Ann Thorac Surg. 2002, 74: 1050-7. 10.1016/S0003-4975(02)03850-X.View ArticlePubMedGoogle Scholar
- Khan MN, Jaïs P, Cummings J, Di Biase L, Sanders P, Martin DO, Kautzner J, Hao S, Themistoclakis S, Fanelli R, Potenza D, Massaro R, Wazni O, Schweikert R, Saliba W, Wang P, Al-Ahmad A, Beheiry S, Santarelli P, Starling RC, Dello Russo A, Pelargonio G, Brachmann J, Schibgilla V, Bonso A, Casella M, Raviele A, Haïssaguerre M, Natale A: Pulmonary vein isolation for atrial fibrillation in patients with heart failure. N Engl J Med. 2008, 359: 1778-85. 10.1056/NEJMoa0708234.View ArticlePubMedGoogle Scholar
- Groh M, Binns O, Burton H, Ely S, Johnson A: Ultrasonic cardiac ablation for atrial fibrillation during concomitant cardiac surgery: Long-term clinical outcomes. Ann Thorac Surg. 2007, 84: 1978-83. 10.1016/j.athoracsur.2007.06.081.View ArticlePubMedGoogle Scholar
- Fukunaga S, Hori H, Ueda T, Takagi K, Tayama E, Aoyagi S: Effect of surgery for atrial fibrillation associated with mitral valve disease. Ann Thorac Surg. 2008, 86: 1212-17. 10.1016/j.athoracsur.2008.05.063.View ArticlePubMedGoogle Scholar
- Jovin A, Oprea DA, Jovin IS, Hashim SW, Clancy JF: Atrial fibrillation and mitral valve repair. Pacing Clin Electrophysiol. 2008, 31: 1057-63. 10.1111/j.1540-8159.2008.01135.x.View ArticlePubMedGoogle Scholar
- Groh M, Binns O, Burton H, Champsaur G, Ely S, Johnson A: Epicardial ultrasonic ablation of atrial fibrillation during concomitant cardiac surgery is a valid option in patients with ischemic heart disease. Circulation. 2008, 118 (suppl 1): S78-S82. 10.1161/CIRCULATIONAHA.107.750927.View ArticlePubMedGoogle Scholar
- Haissaguerre M, Jais P, Shah DC, Takahashi A, Hocini M, Quiniou G, Garrigue S, Le Mouroux A, Le Métayer P, Clémenty J: Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. N Engl J Med. 1998, 339: 659-66. 10.1056/NEJM199809033391003.View ArticlePubMedGoogle Scholar
- Schmitt C, Ndrepepa G, Weber S, Schmieder S, Weyerbrock S, Schneider M, Karch MR, Deisendorf I, Schreieck J, Zrenner B, Schömig A: Biatrial multisite mapping of atrial premature complexes triggering onset of atrial fibrillation. Am J Cardiol. 2002, 89: 1381-7. 10.1016/S0002-9149(02)02350-0.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.